CLINIMIX SOLUTION

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

L-ISOLEUCINE; DEXTROSE; L-LEUCINE HYDROCHLORIDE; L-PHENYLALANINE HYDROCHLORIDE; L-LYSINE HYDROCHLORIDE; METHIONINE; L-ALANINE; GLYCINE; L-ARGININE; L-VALINE; HISTIDINE; L-THREONINE; TRYPTOPHAN; L-PROLINE; L-TYROSINE

Available from:

BAXTER CORPORATION

ATC code:

B05BA10

INN (International Name):

COMBINATIONS

Dosage:

240MG; 5G; 310MG; 310MG; 290MG; 290MG; 1.04G; 1.04G; 520MG; 230MG; 220MG; 210MG; 90MG; 210MG; 20MG

Pharmaceutical form:

SOLUTION

Composition:

L-ISOLEUCINE 240MG; DEXTROSE 5G; L-LEUCINE HYDROCHLORIDE 310MG; L-PHENYLALANINE HYDROCHLORIDE 310MG; L-LYSINE HYDROCHLORIDE 290MG; METHIONINE 290MG; L-ALANINE 1.04G; GLYCINE 1.04G; L-ARGININE 520MG; L-VALINE 230MG; HISTIDINE 220MG; L-THREONINE 210MG; TRYPTOPHAN 90MG; L-PROLINE 210MG; L-TYROSINE 20MG

Administration route:

INTRAVENOUS

Units in package:

1000ML

Prescription type:

Ethical

Therapeutic area:

CALORIC AGENTS

Product summary:

Active ingredient group (AIG) number: 1550853015; AHFS:

Authorization status:

APPROVED

Authorization date:

2013-11-01

Summary of Product characteristics

_Product Monograph Master Template _
_Template Date: September 2020 _
_CLINIMIX (Blend B) _
_Page 1 of 30_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CLINIMIX
Amino Acids without Electrolytes in Dextrose Injection
5% Amino Acids (Blend B) without Electrolytes in 5% Dextrose Injection
5% Amino Acids (Blend B) without Electrolytes in 10% Dextrose
Injection
5% Amino Acids (Blend B) without Electrolytes in 16.6% Dextrose
Injection
5% Amino Acids (Blend B) without Electrolytes in 20% Dextrose
Injection
Solution for Infusion, Intravenous
Intravenous Nutritive Supplements
Baxter Corporation
Mississauga, Ontario
L5N 0C2
Date of Initial Authorization:
DEC 31, 1993
Date of Revision:
APR 1, 2022
Submission Control Number: 256759
Baxter, Clinimix, Clarity and Travasol are registered trademarks of
Baxter International Inc.
_ _
_Product Monograph Master Template _
_Template Date: September 2020 _
_CLINIMIX (Blend B) _
_Page 2 of 30_
RECENT MAJOR LABEL CHANGES
6 Warnings and Precautions
04/2020
3 Dosage and Administration
08/2020
6 Warnings and Precautions
08/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................